SEC Form 4 · accession 0001127602-16-062200
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John F Milligan
Officer — President and CEO · Director
Period of report
Sep 6, 2016
Accepted (ET)
Sep 8, 2016 · 1:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 6, 2016 | M | 70,000 | $20.74 | A | 1,128,963 | D | |
| Common StockF3 | Sep 6, 2016 | S | 70,000 | $77.744 | D | 1,058,963 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F2 | $20.74 | Sep 6, 2016 | M | 70,000 | D | — | May 8, 2017 | Common Stock | 70,000 | 0 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2Options vest over a five year period beginning 5/08/2008, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 5/08/2012.
- F3Sale prices reported for the transactions reported here range from $77.265 to $77.99. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.